Aug 27, 2025
BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®VIEW RELEASE
Aug 26, 2025
BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025VIEW RELEASE
Aug 19, 2025
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Sep 02, 2025 04:00 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
3.8
CHANGE
-0.25 (-6.17%)
